ORIC Pharmaceuticals, Inc. Q4 FY2021 earnings call

Jacob Chacko stated that ORIC-101 clinical trials for GR inhibition in combination with chemotherapy and AR modulators showed no sufficient efficacy signals, leading to discontinuation. The company has a robust pipeline with three INDs filed for ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, with initial data expected in the first half of 2023. The discovery research team advanced a PLK4 program for breast cancer. Cash runway extended to the second half of 2024 due to the discontinuation of ORIC-101.

Cash runway has been extended from the first half of 2024 to the second half of 2024. Expect initial Phase 1 data from ORIC-533, ORIC-114, and ORIC-944 in the first half of 2023.

Tumor heterogeneity and redundant resistance mechanisms could contribute to lack of clinical benefit. Differences in patient populations and treatment regimens compared to other studies (e.g., Corcept's) pose risks to outcomes.

Q: Comment on reasons for lack of benefit with ORIC-101 vs Corcept's results A: Pratik Multani noted differences in patient populations (their study required taxane progression, different prior therapies), and the refractory nature of their patient population. Also, their study had different GCSF use compared to Corcept's.

Q: Learnings from prostate trial for future trials A: Jacob Chacko mentioned ORIC-944 is a different target with potential single agent activity, novel mechanism, and the need to characterize patients for tumor heterogeneity to better understand resistance mechanisms Q: PLK4 program and CNS activity in ORIC-114 A: Jacob Chacko said a PLK4 poster is coming up at ACR, and Pratik Multani stated ORIC-114 allows active pre-mets in Phase 1 eligibility